In this phase I clinical trial, LDRT paired with immunotherapy promoted CD4+ T cell infiltration, induced de novo inflammation, and promoted tumor regression in an IFNγ-dependent manner (7), thus supporting the rationale for combining LDRT with immunotherapy in tumors with low T cell infiltration. The gene discussed is CD4; the disease is neoplasm.